Federal health agencies have temporarily halted the use of the Johnson & Johnson COVID vaccine after several individuals developed life threatening blood clots after receiving the single dose vaccine.
The FDA announced the news after they discovered six women developed a rare form of a blood clot that is difficult to treat. The clot that developed in the women who received the vaccine lowered their platelet counts making the typical treatment for blood clots not an option.
The women who were affected after receiving the vaccine ranged in age from 18 – 48 and developed the clot within two weeks of receiving the Johnson & Johnson vaccine.
One woman died from the clot and an other woman is in the hospital in critical condition.
Anyone who has received the Johnson & Johnson vaccine and develops a severe headache, leg pain, abdominal pain or shortness of breath within three weeks of receiving the vaccine is encouraged to reach out to their healthcare provider.
“We are recommending a pause in the use of this vaccine out of an abundance of caution. Treatment of this specific type of blood clot is different from the treatment that might typically be administered.” – FDA
Approximately 7 million people have already received the Johnson & Johnson vaccine in the United States and an additional 9 million vaccines have been shipped to various states. The FDA is encouraging all states to halt administration of this particular vaccine until a further investigation can be conducted.
A pause after 6 cases of blood clots?
There is clearly something they aren’t telling us. There are more cases of blood clotting due to oral contraceptives that are still being used. #JohnsonandJohnson
— Kimberly Klacik (@kimKBaltimore) April 13, 2021
Last week four different states had to shutdown vaccination sites early due to adverse reactions that were reported from the Johnson & Johnson vaccine.
The FDA will further analyze the cases and assess their significance in regards to the Johnson & Johnson vaccine.
“Until that process is complete, we are recommending this pause. This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot,” – FDA